Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 295-300

  Na, Kyoung Sae ^a   Kim, Won Hyoung ^b   Jung, Han Yong ^a   Ryu, Seong Gon ^c   Min, Kyung Joon ^d   Park, Ki Chang ^e   Kim, Yong Sik ^f   Yoon, Jin Sang ^g   Ahn, Yong Min ^h   Kim, Chul Eung ^b  

^a Soonchunhyang University   (South Korea)

^b Inha University Hospital   (South Korea)

^c Hallym University   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

^e Wonju Severance Christian Hospital   (South Korea)

^f Dongguk University Ilsan Hospital   (South Korea)

^g Chonnam National University   (South Korea)

^h Seoul National University Hospital   (South Korea)

Author keywords

Inflammation; Metabolic syndrome; Paliperidone; Schizophrenia; White blood cells

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CLINICAL TRIAL (TOPIC); CONTROLLED DRUG RELEASE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTENDED DRUG RELEASE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LABORATORY TEST; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); OBESITY; OPEN STUDY; PATIENT MONITORING; POST HOC ANALYSIS; PREDICTIVE VALUE; PROSPECTIVE STUDY; REFERENCE VALUE; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INFLAMMATION; ISOXAZOLES; LEUKOCYTE COUNT; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PYRIMIDINES; SCHIZOPHRENIA;

EID: 84867002349     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.06.024     Document Type: Article

References (41)

1. APA Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association (APA), Washington DC. 4th ed.
2. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010, 196:116-121.
3. Carr D.B., Utzschneider K.M., Hull R.L., Kodama K., Retzlaff B.M., Brunzell J.D., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004, 53:2087-2094.
4. Chen J.J., Lin L.Y., Lee H.H., Lai L.P., Lin J.L., Huang J.J., et al. Association of white blood cell count and peripheral arterial disease in patients with and without traditional risk factors. Angiology 2010, 61:382-387.
5. Chwieduk C.M., Keating G.M. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010, 70:1295-1317.
6. Davidson M., Emsley R., Kramer M., Ford L., Pan G., Lim P., et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007, 93:117-130.
7. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
8. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
9. Emsley R., Berwaerts J., Eerdekens M., Kramer M., Lane R., Lim P., et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008, 23:343-356.
10. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
11. Fan X., Liu E.Y., Freudenreich O., Park J.H., Liu D., Wang J., et al. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 2010, 118:211-217.
12. Fernandez-Egea E., Miller B., Garcia-Rizo C., Bernardo M., Kirkpatrick B. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011, 31:154-159.
13. Foley D.L., Morley K.I. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 2011.
14. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
15. Gu D., Reynolds K., Wu X., Chen J., Duan X., Reynolds R.F., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005, 365:1398-1405.
16. Heng D., Ma S., Lee J.J., Tai B.C., Mak K.H., Hughes K., et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006, 186:367-373.
17. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
18. Kang S.H., Kim K.H., Kang G.Y., Lee K.H., Kim K.K., Soh M., et al. Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia. Schizophr Res 2011, 128:179-181.
19. Levitt N.S., Lambert E.V. The foetal origins of the metabolic syndrome-a South African perspective. Cardiovasc J S Afr 2002, 13:179-180.
20. Lohsoonthorn V., Dhanamun B., Williams M.A. Prevalence of metabolic syndrome and its relationship to white blood cell count in a population of Thai men and women receiving routine health examinations. Am J Hypertens 2006, 19:339-345.
21. Marder S.R., Kramer M., Ford L., Eerdekens E., Lim P., Eerdekens M., et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-1370.
22. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
23. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 2009, 66:1013-1022.
24. NCEP Expert Panel Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
25. Oda E., Kawai R. The prevalence of metabolic syndrome and diabetes increases through the quartiles of white blood cell count in Japanese men and women. Intern Med 2009, 48:1127-1134.
26. Padmavati R., McCreadie R.G., Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res 2010, 121:199-202.
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
28. Reaven G.M., Chen Y.D. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 1988, 4:639-652.
29. Reilly M.P., Rader D.J. The metabolic syndrome: more than the sum of its parts?. Circulation 2003, 108:1546-1551.
30. Ryan M.C., Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002, 71:239-257.
31. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Metabolic syndrome in first episode schizophrenia-a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008, 101:266-272.
32. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007, 64:1123-1131.
33. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ying Kin N., Stip E., et al. Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?. Schizophr Res 2008, 102:329-336.
34. Shankar A., Mitchell P., Rochtchina E., Wang J.J. The association between circulating white blood cell count, triglyceride level and cardiovascular and all-cause mortality: population-based cohort study. Atherosclerosis 2007, 192:177-183.
35. Snijder M.B., Visser M., Dekker J.M., Seidell J.C., Fuerst T., Tylavsky F., et al. The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. Int J Obes Relat Metab Disord 2002, 26:984-993.
36. Sugawara N., Yasui-Furukori N., Sato Y., Umeda T., Kishida I., Yamashita H., et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010, 123:244-250.
37. Victoriano M., de Beaurepaire R., Naour N., Guerre-Millo M., Quignard-Boulange A., Huneau J.F., et al. Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. Brain Res 2010, 1350:167-175.
38. Weiden P.J. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 2007, 68(Suppl. 4):34-39.
39. WHO Western Pacific Region The Asia-Pacific perspective. Redefining obesity and its treatment 2000, WHO/IASO/IOTF.
40. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292:2237-2242.
41. Yang L.P., Plosker G.L. Paliperidone extended release. CNS Drugs 2007, 21:417-425. [discussion 26-7].